Cambridgeshire and Peterborough NHS Foundation Trust launches mental health clinical trials
pharmafile | February 4, 2019 | News story | Sales and Marketing | UK, clinical trials, clozapine, mental health, schizophrenia
The Cambridgeshire and Peterborough NHS Foundation Trust’s Windsor Research Unit is offering patients the chance to participate in clinical trials for new mental health treatments and therapies.
The trust – one of the leading mental health research trusts – are investigating ways through which mental illness can be diagnosed at the earliest stage, as they explore the links between mental and physical illnesses, and improve care and support for patients.
The unit’s mental health team manager, Katherine Cummergen, commented: “We are delighted to start running clinical trials as part of the mental health research portfolio and work with new health partners to test pioneering treatments. The team is dedicated to giving patients and volunteers the best experience and increasing opportunities to take part in research to enhance their care so we can find solutions to improve mental health.”
Anyone who has been diagnosed with schizophrenia can ask their doctor whether the trust’s trial for the antipsychotic medication clozapine may be helpful. The doctor will be able to refer patients to the trial.
Consultant psychiatrist Dr Emilio Fernandez-Egea said: “Research is essential to improve clinical care for our patients. At the Clozapine Clinic I work with many people living with treatment-resistant schizophrenia and want to offer them every chance to try new treatments and therapies. The mental health team at Windsor Research Unit offer fantastic support for researchers and health professionals and this development means we can now integrate clinical trials with care.”
Louis Goss
Related Content
Men’s health – a new report from the Department of Health and Social Care
The UK Department of Health and Social Care has published a new report entitled Men’s …
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
